Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) will announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Wednesday, February 28th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $1.44 million. During the same quarter in the prior year, the company earned ($0.64) EPS. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Stock Down 1.0 %

Iovance Biotherapeutics stock traded down $0.14 during midday trading on Tuesday, reaching $13.74. 1,135,676 shares of the company traded hands, compared to its average volume of 8,070,639. The business has a 50 day moving average of $13.91 and a two-hundred day moving average of $9.63. Iovance Biotherapeutics has a 12 month low of $3.21 and a 12 month high of $18.33.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, February 29th. Barclays upped their price target on shares of Iovance Biotherapeutics from $18.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a report on Friday, February 2nd. Chardan Capital upped their target price on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, February 20th. Finally, Piper Sandler lifted their price target on shares of Iovance Biotherapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, March 14th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.64.

Insiders Place Their Bets

In other Iovance Biotherapeutics news, Director Merrill A. Mcpeak bought 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $9.15 per share, with a total value of $2,287,500.00. Following the purchase, the director now owns 320,150 shares of the company’s stock, valued at $2,929,372.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.40% of the stock is currently owned by company insiders.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.